CLSA: Raises Fosun Pharma (02196.HK) H-share target price by 1.9% to HK$27.1, maintains "Outperform" rating

Zhitong Finance APP has learned that CLSA released a research report stating that it has raised the H-share target price of Fosun Pharma (02196, 600196.SH) by 1.9%, from HK$26.6 to HK$27.1, and also raised the A-share target price, maintaining an "Outperform" rating. The bank said that Fosun Pharma's third-quarter results were basically in line with expectations, with steady growth in innovative product sales driving margin improvement.